Conference Coverage
Conference Coverage
ZUMA-5: Axi-cel yields high response rate in indolent NHL
The CAR T-cell therapy had a favorable safety profile and a median duration of response that had not been reached at a median of 17.5 months...
Conference Coverage
COVID-19–related outcomes poor for patients with hematologic disease in ASH registry
Conference Coverage
CAR T for all R/R DLBCL patients: The jury is still out
Conference Coverage
Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL
Article
Efforts to close the ‘AYA gap’ in lymphoma
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.
Conference Coverage
Ibrutinib-venetoclax produces high MRD-negative rates in CLL/SLL
Minimal residual disease was undetectable in peripheral blood of 75% of patients after an ibrutinib lead-in and 12 cycles of the combination.
Conference Coverage
Three-drug combo promising against high-risk CLL
Conference Coverage
Adding avadomide shows promise for newly diagnosed DLBCL
Conference Coverage
MCC response varies based on immunosuppression type, especially CLL